On Tuesday, investors hope to learn Pfizer Inc’s plans for what could be a once in a generation cash infusion from COVID-19 treatments and vaccines in 2022. Some drugmakers are looking to spend on potential acquisitions. According to Chief Executive Albert… Read More ›
Belgian drugmaker Galapagos NV has named former Johnson & Johnson senior executive Paul Stoffels as its CEO, effective from April 1, 2022. Since 2012, Stoffels was the chief scientific officer at Johnson & Johnson and has spearheaded the development of its single-shot… Read More ›
In a joint statement Danish drugmaker Novo Nordisk and U.S. drug developer Prothena Corp said, the former will acquire the latter’s experimental heart therapy PRX004, in a deal that could be worth up to $1.23 billion. Novo’s acquisition is in… Read More ›
In a statement, Bristol-Myers Squibb Co and Eisai Co said, they had entered into an agreement to jointly develop and market an experimental cancer drug worth up to $3.10 billion. Bristol-Myers would pay $650 million, including for research and development… Read More ›
Sanofi’s strength in molecular oncology is likely to provide it a competitive edge over its peers as to what drives the growth of cancer tissues, how these cells functions and proliferation in the body. In a strategic development, French drugmaker,… Read More ›
The deal, one of the largest in the pharma industry, will place Takeda Pharma into the top ranks of global drugmakers. On Tuesday, in a strategic move Japan’s Takeda Pharma stated it has agreed to acquire London-listed Shire for $61.50… Read More ›
manageria.biz 